Table 2 Risk of cancer in biologic-naïve and TNFi-treated RA patients compared with the Australian general population, and relative risk in the TNFi treated patients compared to biologic naïve patients

Site

O

E

SIR (95 % CI)

O

E

SIR (95 % CI)

RR (95 % CI)^b

All invasive cancers

32

23.38

1.37 (0.97, 1.94)

44

56.78

0.77 (0.58, 1.04)

0.65 (0.37, 1.17)

Melanoma

5

1.84

2.72 (1.13, 6.53)

10

4.92

2.03 (1.09, 3.78)

0.54 (0.12, 2.40)

Lung

6

2.41

2.49 (1.12, 5.53)

4

5.23

0.77 (0.29, 2.04)

0.24 (0.05, 1.17)

Lymphoid cancers^a

1

1.49

0.67 (0.09, 4.76)

6

3.54

1.69 (0.76, 3.77)

4.01 (0.18, 88.19)

Colorectal

2

3.41

0.59 (0.15, 2.35)

1

7.75

0.13 (0.02, 0.92)

0.06 (0.001, 3.28)

Prostate

5

3.38

1.48 (0.62, 3.55)

7

7.71

0.91 (0.43, 1.90)

1.21 (0.33, 4.45)

Female breast

5

3.32

1.51 (0.63, 3.62)

4

10.29

0.39 (0.15, 1.04)

0.17 (0.03, 0.95)